Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy

Lung Cancer ◽  
2013 ◽  
Vol 81 (2) ◽  
pp. 236-240 ◽  
Author(s):  
Francesco Grossi ◽  
Carlo Genova ◽  
Nidia Diaz Gaitan ◽  
Maria Giovanna Dal Bello ◽  
Erika Rijavec ◽  
...  
Keyword(s):  
Clinical Trials ◽  
National Health Service ◽  
Health Service ◽  
Cost Saving ◽  
Cost Analysis ◽  
National Health ◽  
Potential Cost Saving ◽  
Potential Cost

scholarly journals Setting up clinical research studies in the National Health Service in England

2016 ◽  
Vol 10 (2) ◽  
pp. 145-147 ◽  
Author(s):  
Jessica Whitburn ◽  
Surjeet Singh ◽  
Prasanna Sooriakumaran
Keyword(s):  
Clinical Trials ◽  
National Health Service ◽  
Health Service ◽  
Research And Development ◽  
Clinical Research ◽  
National Health ◽  
Health Research ◽  
Application Process ◽  
Regulatory Bodies ◽  
Research Studies

Starting and conducting clinical trials in England can be a complicated and time-consuming process. Before your study can begin it is necessary to gain approval from the appropriate regulatory bodies. Prior to March 2016, studies required National Health Service (NHS) permission (also referred to as Research and Development (R&D) approval) obtained via the National Institute for Health Research (NIHR) Coordinated System for gaining NHS Permission (CSP). Since March 2016, a new streamlined system has been introduced with the aim of making it easier to gain regulatory approvals. Now studies must go through the process of Health Research Authority (HRA) approval. In this article we review the process of gaining HRA approval in England. The article is aimed at junior researchers to help them understand the application process, and to give tips on how to succeed in gaining approval.

scholarly journals Impact of the Manchester Glaucoma Enhanced Referral Scheme on NHS costs

2019 ◽  
Vol 4 (1) ◽  
pp. e000278 ◽  
Author(s):  
Hannah Forbes ◽  
Matt Sutton ◽  
David F Edgar ◽  
John Lawrenson ◽  
Anne Fiona Spencer ◽  
...  
Keyword(s):  
National Health Service ◽  
Health Service ◽  
Observational Study ◽  
Cost Analysis ◽  
National Health ◽  
False Positive ◽  
Waiting Times ◽  
Outpatient Visits ◽  
Audit Data ◽  
The Cost

ObjectivesGlaucoma filtering schemes such as the Manchester Glaucoma Enhanced Referral Scheme (GERS) aim to reduce the number of false positive cases referred to Hospital Eye Services. Such schemes can also have wider system benefits, as they may reduce waiting times for other patients. However, previous studies of the cost consequences and wider system benefits of glaucoma filtering schemes are inconclusive. We investigate the cost consequences of the Manchester GERS.DesignObservational study.MethodsA cost analysis from the perspective of the National Health Service (NHS) was conducted using audit data from the Manchester GERS.Results2405 patients passed through the Manchester GERS from April 2013 to November 2016. 53.3% were not referred on to Manchester Royal Eye Hospital (MREH). Assuming an average of 2.3 outpatient visits to MREH were avoided for each filtered patient, the scheme saved the NHS approximately £2.76 per patient passing through the scheme.ConclusionOur results indicate that glaucoma filtering schemes have the potential to reduce false positive referrals and costs to the NHS.

scholarly journals 140. PATIENT SATISFACTION WITH PARTICIPATION IN CLINICAL TRIALS IN A NATIONAL HEALTH SERVICE SETTING

Rheumatology ◽  
2017 ◽  
Vol 56 (suppl_2) ◽  
Author(s):  
Izolda Biro ◽  
Simon Donnelly ◽  
Carey Tierney ◽  
Hasan Tahir ◽  
Judith Bubbear
Keyword(s):  
Clinical Trials ◽  
Patient Satisfaction ◽  
National Health Service ◽  
Health Service ◽  
National Health ◽  
Service Setting
Sign in / Sign up

Export Citation Format

Share Document